vs
Side-by-side financial comparison of RECURSION PHARMACEUTICALS, INC. (RXRX) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.
VERACYTE, INC. is the larger business by last-quarter revenue ($140.6M vs $35.5M, roughly 4.0× RECURSION PHARMACEUTICALS, INC.). VERACYTE, INC. runs the higher net margin — 29.3% vs -304.2%, a 333.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 18.5%). VERACYTE, INC. produced more free cash flow last quarter ($48.8M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 20.5%).
Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.
Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.
RXRX vs VCYT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.5M | $140.6M |
| Net Profit | $-108.1M | $41.1M |
| Gross Margin | 59.8% | 72.5% |
| Operating Margin | -304.8% | 26.4% |
| Net Margin | -304.2% | 29.3% |
| Revenue YoY | 681.7% | 18.5% |
| Net Profit YoY | 39.6% | 704.8% |
| EPS (diluted) | $-0.17 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.5M | $140.6M | ||
| Q3 25 | $5.2M | $131.9M | ||
| Q2 25 | $19.2M | $130.2M | ||
| Q1 25 | $14.7M | $114.5M | ||
| Q4 24 | $4.5M | $118.6M | ||
| Q3 24 | $26.1M | $115.9M | ||
| Q2 24 | $14.4M | $114.4M | ||
| Q1 24 | $13.8M | $96.8M |
| Q4 25 | $-108.1M | $41.1M | ||
| Q3 25 | $-162.3M | $19.1M | ||
| Q2 25 | $-171.9M | $-980.0K | ||
| Q1 25 | $-202.5M | $7.0M | ||
| Q4 24 | $-178.9M | $5.1M | ||
| Q3 24 | $-95.8M | $15.2M | ||
| Q2 24 | $-97.5M | $5.7M | ||
| Q1 24 | $-91.4M | $-1.9M |
| Q4 25 | 59.8% | 72.5% | ||
| Q3 25 | -183.8% | 69.2% | ||
| Q2 25 | -4.9% | 69.0% | ||
| Q1 25 | -48.0% | 69.5% | ||
| Q4 24 | -181.4% | 66.4% | ||
| Q3 24 | 53.7% | 68.2% | ||
| Q2 24 | 36.2% | 68.1% | ||
| Q1 24 | 19.1% | 64.5% |
| Q4 25 | -304.8% | 26.4% | ||
| Q3 25 | -3327.6% | 17.4% | ||
| Q2 25 | -916.8% | -4.0% | ||
| Q1 25 | -1297.9% | 2.5% | ||
| Q4 24 | -4042.4% | 3.5% | ||
| Q3 24 | -377.1% | 10.4% | ||
| Q2 24 | -697.4% | 4.0% | ||
| Q1 24 | -698.4% | -4.8% |
| Q4 25 | -304.2% | 29.3% | ||
| Q3 25 | -3135.3% | 14.5% | ||
| Q2 25 | -894.2% | -0.8% | ||
| Q1 25 | -1373.3% | 6.2% | ||
| Q4 24 | -3935.5% | 4.3% | ||
| Q3 24 | -367.5% | 13.1% | ||
| Q2 24 | -676.6% | 5.0% | ||
| Q1 24 | -662.4% | -1.9% |
| Q4 25 | $-0.17 | $0.50 | ||
| Q3 25 | $-0.36 | $0.24 | ||
| Q2 25 | $-0.41 | $-0.01 | ||
| Q1 25 | $-0.50 | $0.09 | ||
| Q4 24 | $-0.56 | $0.07 | ||
| Q3 24 | $-0.34 | $0.19 | ||
| Q2 24 | $-0.40 | $0.07 | ||
| Q1 24 | $-0.39 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $743.3M | $362.6M |
| Total DebtLower is stronger | $9.6M | — |
| Stockholders' EquityBook value | $1.1B | $1.3B |
| Total Assets | $1.5B | $1.4B |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $743.3M | $362.6M | ||
| Q3 25 | $659.8M | $315.6M | ||
| Q2 25 | $525.1M | $219.5M | ||
| Q1 25 | $500.5M | $186.1M | ||
| Q4 24 | $594.4M | $239.1M | ||
| Q3 24 | $427.6M | $274.1M | ||
| Q2 24 | $474.3M | $235.9M | ||
| Q1 24 | $296.3M | $209.2M |
| Q4 25 | $9.6M | — | ||
| Q3 25 | $11.9M | — | ||
| Q2 25 | $14.2M | — | ||
| Q1 25 | $16.4M | — | ||
| Q4 24 | $19.0M | — | ||
| Q3 24 | $20.5M | — | ||
| Q2 24 | $22.9M | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $919.1M | $1.2B | ||
| Q1 25 | $933.9M | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $524.6M | $1.2B | ||
| Q2 24 | $584.4M | $1.1B | ||
| Q1 24 | $401.2M | $1.1B |
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $726.5M | $1.3B | ||
| Q2 24 | $775.9M | $1.2B | ||
| Q1 24 | $557.8M | $1.2B |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-46.1M | $52.6M |
| Free Cash FlowOCF − Capex | $-47.3M | $48.8M |
| FCF MarginFCF / Revenue | -133.1% | 34.7% |
| Capex IntensityCapex / Revenue | 3.5% | 2.7% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $-378.3M | $126.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-46.1M | $52.6M | ||
| Q3 25 | $-117.4M | $44.8M | ||
| Q2 25 | $-76.4M | $33.6M | ||
| Q1 25 | $-132.0M | $5.4M | ||
| Q4 24 | $-115.4M | $24.5M | ||
| Q3 24 | $-59.2M | $30.0M | ||
| Q2 24 | $-82.2M | $29.6M | ||
| Q1 24 | $-102.3M | $-9.0M |
| Q4 25 | $-47.3M | $48.8M | ||
| Q3 25 | $-117.6M | $42.0M | ||
| Q2 25 | $-79.6M | $32.3M | ||
| Q1 25 | $-133.8M | $3.5M | ||
| Q4 24 | $-116.7M | $20.4M | ||
| Q3 24 | $-63.8M | $27.7M | ||
| Q2 24 | $-83.4M | $26.8M | ||
| Q1 24 | $-109.0M | $-11.1M |
| Q4 25 | -133.1% | 34.7% | ||
| Q3 25 | -2272.5% | 31.8% | ||
| Q2 25 | -413.9% | 24.8% | ||
| Q1 25 | -907.4% | 3.1% | ||
| Q4 24 | -2567.7% | 17.2% | ||
| Q3 24 | -244.6% | 23.9% | ||
| Q2 24 | -578.5% | 23.4% | ||
| Q1 24 | -789.9% | -11.5% |
| Q4 25 | 3.5% | 2.7% | ||
| Q3 25 | 4.7% | 2.1% | ||
| Q2 25 | 16.4% | 1.0% | ||
| Q1 25 | 12.4% | 1.6% | ||
| Q4 24 | 28.6% | 3.5% | ||
| Q3 24 | 17.5% | 1.9% | ||
| Q2 24 | 8.2% | 2.4% | ||
| Q1 24 | 48.2% | 2.2% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RXRX
Segment breakdown not available.
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
